How obesity is defined shapes who gets treated, when, and with what urgency — making the Lancet Diabetes & Endocrinology Commission's new classification framework one of the more consequential diagnostic proposals in recent metabolic medicine. The Endocrine Society's independent appraisal cuts to the heart of a tension that will affect millions of adults: does a more precise definition of obesity improve care, or inadvertently create barriers to it?
The Lancet framework proposes retiring BMI as the primary diagnostic criterion, replacing it with direct or surrogate measures of excess adiposity. It then stratifies patients into two distinct categories: "clinical obesity," defined by measurable organ or system dysfunction attributable to excess fat, and "preclinical obesity," where adiposity is elevated but objective dysfunction has not yet emerged. Validation analyses from large-scale biobanks — including All of Us and the UK Biobank — confirm that even preclinical classifications carry meaningfully elevated cardiometabolic risk, with clinical obesity conferring even higher risk. Central adiposity and fat distribution patterns outperform BMI alone in predicting metabolic harm. However, the appraisal flags critical gaps: no standardized anthropometric measurement protocols exist, resource demands for implementation are substantial, and the framework inadequately distinguishes between visceral and subcutaneous fat depots — a clinically meaningful distinction given visceral fat's disproportionate contribution to insulin resistance and cardiovascular risk.
This appraisal lands at a pivotal moment. The proliferation of GLP-1 receptor agonists has intensified debates about which patients qualify for pharmacological intervention and whether insurers will follow diagnostic reclassifications. The preclinical/clinical split risks creating a coverage gap that disproportionately affects lower-income patients who lack access to advanced body composition testing. Historically, BMI's crudeness was offset by its universality and low cost — replacing it demands robust infrastructure that most clinical settings globally do not yet possess. The framework represents genuine conceptual progress, but the Endocrine Society's caution is warranted: precision diagnostics without equitable implementation infrastructure can widen, rather than close, health disparities.